These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 1664137)

  • 1. Cytotoxic T cells specific for cytomegalovirus: a potential therapy for immunocompromised patients.
    Riddell SR; Reusser P; Greenberg PD
    Rev Infect Dis; 1991; 13 Suppl 11():S966-73. PubMed ID: 1664137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor.
    Walter EA; Greenberg PD; Gilbert MJ; Finch RJ; Watanabe KS; Thomas ED; Riddell SR
    N Engl J Med; 1995 Oct; 333(16):1038-44. PubMed ID: 7675046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective reconstitution of CD8+ cytotoxic T lymphocyte responses in immunodeficient bone marrow transplant recipients by the adoptive transfer of T cell clones.
    Riddell SR; Walter BA; Gilbert MJ; Greenberg PD
    Bone Marrow Transplant; 1994; 14 Suppl 4():S78-84. PubMed ID: 7728132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a treatment regimen for human cytomegalovirus (CMV) infection in bone marrow transplantation recipients by adoptive transfer of donor-derived CMV-specific T cell clones expanded in vitro.
    Greenberg PD; Reusser P; Goodrich JM; Riddell SR
    Ann N Y Acad Sci; 1991 Dec; 636():184-95. PubMed ID: 1665321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis.
    Li CR; Greenberg PD; Gilbert MJ; Goodrich JM; Riddell SR
    Blood; 1994 Apr; 83(7):1971-9. PubMed ID: 8142663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenesis of cytomegalovirus pneumonia in immunocompromised hosts.
    Riddell SR
    Semin Respir Infect; 1995 Dec; 10(4):199-208. PubMed ID: 8668847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants.
    Lucas KG; Sun Q; Burton RL; Tilden A; Vaughan WP; Carabasi M; Salzman D; Ship A
    Hum Gene Ther; 2000 Jul; 11(10):1453-63. PubMed ID: 10910142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive immunotherapy for cytomegalovirus (CMV) disease in immunocompromised patients.
    Lim JB; Kwon OH; Kim HS; Kim HO; Choi JR; Provenzano M; Stroncek D
    Yonsei Med J; 2004 Jun; 45 Suppl():18-22. PubMed ID: 15250045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease.
    Reusser P; Riddell SR; Meyers JD; Greenberg PD
    Blood; 1991 Sep; 78(5):1373-80. PubMed ID: 1652311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines.
    Peggs KS; Verfuerth S; Pizzey A; Khan N; Guiver M; Moss PA; Mackinnon S
    Lancet; 2003 Oct; 362(9393):1375-7. PubMed ID: 14585640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT.
    Neuenhahn M; Albrecht J; Odendahl M; Schlott F; Dössinger G; Schiemann M; Lakshmipathi S; Martin K; Bunjes D; Harsdorf S; Weissinger EM; Menzel H; Verbeek M; Uharek L; Kröger N; Wagner E; Kobbe G; Schroeder T; Schmitt M; Held G; Herr W; Germeroth L; Bonig H; Tonn T; Einsele H; Busch DH; Grigoleit GU
    Leukemia; 2017 Oct; 31(10):2161-2171. PubMed ID: 28090089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytomegalovirus-specific T-cell immunity in recipients of autologous peripheral blood stem cell or bone marrow transplants.
    Reusser P; Attenhofer R; Hebart H; Helg C; Chapuis B; Einsele H
    Blood; 1997 May; 89(10):3873-9. PubMed ID: 9160696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expansion of cytomegalovirus pp65 and IE-1 specific cytotoxic T lymphocytes for cytomegalovirus-specific immunotherapy following allogeneic stem cell transplantation.
    Bao L; Dunham K; Stamer M; Mulieri KM; Lucas KG
    Biol Blood Marrow Transplant; 2008 Oct; 14(10):1156-1162. PubMed ID: 18804046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for transfer of cellular and humoral immunity to cytomegalovirus from donor to recipient in allogeneic bone marrow transplantation.
    Boland GJ; Vlieger AM; Ververs C; De Gast GC
    Clin Exp Immunol; 1992 Jun; 88(3):506-11. PubMed ID: 1318805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of cytotoxic T lymphocytes specific for human cytomegalovirus using dendritic cells in vitro.
    Cho HI; Han H; Kim CC; Kim TG
    J Immunother; 2001; 24(3):242-9. PubMed ID: 11394502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune donors can protect marrow-transplant recipients from severe cytomegalovirus infections.
    Grob JP; Grundy JE; Prentice HG; Griffiths PD; Hoffbrand AV; Hughes MD; Tate T; Wimperis JZ; Brenner MK
    Lancet; 1987 Apr; 1(8536):774-6. PubMed ID: 2882184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid expansion of cytomegalovirus-specific cytotoxic T lymphocytes by artificial antigen-presenting cells expressing a single HLA allele.
    Papanicolaou GA; Latouche JB; Tan C; Dupont J; Stiles J; Pamer EG; Sadelain M
    Blood; 2003 Oct; 102(7):2498-505. PubMed ID: 12805061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adoptive immunotherapy of HCMV infection.
    Kapp M; Tan SM; Einsele H; Grigoleit G
    Cytotherapy; 2007; 9(8):699-711. PubMed ID: 17917875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical-scale isolation of 'minimally manipulated' cytomegalovirus-specific donor lymphocytes for the treatment of refractory cytomegalovirus disease.
    Odendahl M; Grigoleit GU; Bönig H; Neuenhahn M; Albrecht J; Anderl F; Germeroth L; Schmitz M; Bornhäuser M; Einsele H; Seifried E; Busch DH; Tonn T
    Cytotherapy; 2014 Sep; 16(9):1245-56. PubMed ID: 25108651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Monitoring of cytomegalovirus-specific CD4+ and CD8+ T cell responses by cytokine flow cytometry in renal transplant recipients].
    Kılınçkaya Doğan H; Mutlu E; Köksoy S; Yılmaz VT; Koçak H; Çolak D; Mutlu D; Günseren F; Dinçkan A; Aliosmanoğlu İ; Süleymanlar G; Gültekin M
    Mikrobiyol Bul; 2016 Apr; 50(2):224-35. PubMed ID: 27175495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.